Objective:To investigate the efficacy of omalizumab combined with fluticasone propionate in the treatment of allergic asthma(AA)in children.Methods:A total of 100 AA children were divided into control group and observation group according to dif-ferent treatment methods,with 50 cases in each group.The control group was treated with fluticasone propionate,and the observation group was treated with omalizumab combined with fluticasone propionate.Both groups were treated for 4 months.Children's Asthma Con-trol Test(C-ACT),daytime and nighttime symptom scores of asthma were recorded before and after treatment in the two groups.Lung function[forced expiratory volume in the first second(FEV1),maximum expiratory flow(PEF)]and serum immunoglobulin E(IgE),C-reactive protein(CRP),interleukin-6(IL-6),transforming growth factor-β1(TGF-β1)and matrix metalloproteinase-9(MMP-9)levels were detected.The therapeutic effects were recorded and compared between the two groups.Results:The total effective rate of the observation group was higher than that of the control group(94.00%vs.80.00%,P<0.05).After treatment,compared with the con-trol group,the C-ACT score,FEV1 and PEF in the observation group were higher(P<0.05),and the daytime and nighttime scores of asthma were lower(P<0.05).After treatment,the levels of serum IgE,CRP,IL-6,TGF-β1 and MMP-9 in the observation group were lower than those in the control group(P<0.05).Conclusion:On the basis of fluticasone propionate treatment,the addition of omalizumab can relieve asthma symptoms,reduce inflammation levels,inhibit airway remodeling,and improve lung function in children with AA.